ALK and non-small cell lung carcinoma: Crizotinib is a multikinase inhibitor (MKI) with activity against ROS1, ALK, and mesenchymal-epidermal transition (MET).4,37 The FDA approval of crizotinib for the treatment of patients with advanced ROS1+ NSCLC was based on the results from a multicenter phase I trial PROFILE 1001, which demonstrated an objective response rate (ORR) of 72% and median progression-free survival (mPFS) of 19.2 months in this patient population.4,21 The most frequent adverse events (AEs) include visual impairment, nausea, vomiting, diarrhea, constipation, edema, and elevated aminotransferase levels.